MercifulKnight
Our return YTD is +20.57% βœ… Versus $SPX500 (SPX500 Index (Non Expiry)) YTD -3.31% πŸ”» 23.88% above our benchmark πŸš€πŸš€πŸš€ Our second position $NVO (Novo-Nordisk A/S SPONS ADR) is scheduled to announce its Q1 2025 earnings results on Wednesday, May 7, 2025, at 07:30 CEST πŸ“Š Analyst Forecasts Earnings Per Share (EPS): Analysts estimate an EPS of $0.92 for Q1 2025. Revenue: The consensus revenue forecast is approximately $9.23 billion. πŸ“ˆ Company Outlook Novo Nordisk has projected 2025 sales growth between 16% and 24%, a deceleration compared to the 26% growth reported in 2024. This adjustment reflects increased competition in the obesity drug market, particularly from Eli Lilly's Zepbound, which has surpassed Wegovy in weekly prescriptions. Despite these challenges, Novo Nordisk continues to expand its patient base, now serving over 45 million individuals with diabetes and obesity treatments. The company is also investing in research and development, with advancements in its CagriSema trials and the introduction of semaglutide 7.2 mg and amycretin. Have a nice evening! David $NSDQ100 (NASDAQ100 Index (Non Expiry)) $NVDA (NVIDIA Corporation) $MU (Micron Technology, Inc.)
Like CommentShare
1 reply
3 replies
1 reply
1 reply
null
.